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Abstract
Background: The aim of the current study was to assess the antidepressant efficacy and safety of Hypericum perforatum
(St. John's wort) extract WS® 5570 at doses of 600 mg/day in a single dose and 1200 mg/day in two doses.
Methods: The participants in this double-blind, randomized, placebo-controlled, multi-center clinical trial were male and
female adult out-patients with an episode of mild or moderate major depressive episode (single or recurrent episode,
DSM-IV criteria). As specified by the relevant guideline, the study was preceded by a medication-free run-in phase. For
the 6-week treatment, 332 patients were randomized: 123 to WS® 5570 600 mg/day, 127 to WS® 5570 1200 mg/day,
and 82 to placebo. The primary outcome measure was the change in total score on the Hamilton Rating Scale for
Depression (HAM-D, 17-item version) between baseline and endpoint. Additional measures included the number of
responders, the number of patients in remission, and several other standard rating scales. Efficacy and safety were
assessed after 2 and 6 weeks. The design included an interim analysis performed after randomization with the option of
early termination.
Results: After 6 weeks of treatment, mean ± standard deviation decreases in HAM-D total scores of 11.6 ± 6.4, 10.8 ±
7.3, and 6.0 ± 8.1 points were observed for the WS® 5570 600 mg/day, 1200 mg/day and placebo groups, respectively
(endpoint analysis). Secondary measures of treatment efficacy also showed that both WS® 5570 groups were statistically
superior to placebo. Significantly more patients in the WS® 5570 treatment groups than in the placebo group showed
treatment response and remission. WS® 5570 was consistently more effective than placebo in patients with either less
severe or more severe baseline impairment. The number of patients who experienced remission was higher in the WS®
5570 1200 mg/day group than the WS® 5570 600 mg/day group. The incidence of adverse events was low in all groups.
The adverse event profile was consistent with the known profile for Hypericum extract preparations.
Conclusion: Hypericum perforatum extract WS® 5570 at doses of 600 mg/day (once daily) and 1200 mg/day (600 mg
twice daily) were found to be safe and more effective than placebo, with comparable efficacy of the WS® 5570 groups
for the treatment of mild to moderate major depression.
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Background
St. John's wort (Hypericum perforatum extract) is an attrac-
tive treatment option for patients with mild to moderately
severe depression because it has been shown in clinical tri-
als to be effective [1-6] and well tolerated with a more
favorable side-effect profile than many synthetic antide-
pressants [2,6-10]. The use of preparations of St. John's
wort extracts for patients with major depression, however,
remains somewhat controversial, since some studies in
major depression showed no significant effect [e.g.
[11,13]]. Recent meta-analyses of randomized double-
blind trials that tested the efficacy of St. John's wort
extracts against either placebo or standard antidepressants
[14-16] have shown the current evidence as to whether
the effects are marked or minor in patients with major
depression to be inconsistent and confusing.
Experimental investigations have provided evidence that
serotonin receptor expression is markedly reduced during
treatment with Hypericum extract, ultimately leading to
enhanced synaptic availability of serotonin and norepine-
phrin [17,18].
St. John's wort preparations are extracted from the plant's
flowers and leaves, harvested just before or during the
flowering period. The ingredients include hypericin along
with flavonoids, xanthone derivates, plant acids (chloro-
genic acid, caffeic acid), tannins (catechin) and the phlo-
roglucin hyperforin. The inhibition of neuronal uptake of
serotonin and other biogenic amines and amino acid neu-
rotransmitters is probably mainly attributable to hyper-
forin.
The therapeutic profile of St. John's wort extract in the
treatment of mild to moderate depression is rather gen-
eral, influencing all signs and symptoms of the disease,
similar to the profile of serotonin uptake inhibitors [14].
Whether there is a relationship between the initial severity
of the patient's depression and the efficacy of St. John's
wort extract has important clinical implications. Laak-
mann et al. [2] investigated St. John's wort extract in
mildly to moderately depressed patients with a baseline
total score on the Hamilton Rating Scale for Depression
(HAM-D, 17-item version) of 17 or higher. The results
suggested that the more severely depressed subgroup
(those with an initial total score on the HAM-D scale of 22
or higher) experienced greater antidepressant benefit from
treatment with St. John's wort extract than the less severely
depressed subgroup.
The safety and efficacy of the St. John's wort extract WS®
5570 have been successfully investigated in recent studies.
Lecrubier et al. [4] demonstrated the efficacy of WS® 5570
at a dose of 300 mg three times daily for 6 weeks, showing
it to be safe and more effective than placebo in patients
with mild to moderate major depression. In addition, WS®
5570 300 mg three times daily was demonstrated to be at
least equally effective and better tolerated than paroxetine
in patients with moderate to severe depression [19].
The optimal dosage and dose regimen of St. John's wort
extract have not been definitively established. A total daily
dose of 2–4 g of St. John's wort has been recommended by
the Commission E Monographs [20]. Most of the availa-
ble clinical data have been carried out for 300 mg prepa-
rations of St. John's wort extract taken three times daily. In
a postmarketing survey with 2166 patients, Rychlik et al.
[21] demonstrated an improvement in depressive symp-
toms with 600 mg St. John's wort extract taken once or
twice daily similar to that observed with 300 mg three
times daily. The current study was designed to assess the
antidepressant efficacy and safety of St. John's wort extract
WS® 5570 at doses of 600 mg/day (given only once daily)
and 1200 mg/day (given as 600 mg twice daily) over 6
weeks of treatment in patients suffering from a major
depressive episode.
Methods
Protocol, design and objectives
This was a 6-week randomized, double-blind, placebo-
controlled, multi-center, clinical phase III trial comparing
the efficacy of St. John's wort extract WS® 5570 600 mg/
day (in one dose) and 1200 mg/day (in two 600 mg
doses) with placebo in patients suffering from a mild or
moderate major depressive episode according to DSM-IV
[21]. The investigation was conducted between April 2003
and August 2004 at 16 centers (11 psychiatrists, 5 general
practitioners) in Germany. It followed the Good Clinical
Practice guidelines of the European Union, the Declara-
tion of Helsinki, and German regulatory and legal require-
ments. An independent ethics committee (EC of
Landesärztekammer Baden-Württemberg, Germany)
approved the trial protocol prior to study initiation (code
227-02). All patients provided written informed consent.
In accordance with EMEA guidance on the performance of
clinical investigations of medicinal products in the treat-
ment of depression, the 6-week treatment period was not
preceded by a placebo wash-out period and established
rating scales were used to assess antidepressant efficacy.
The raters were blind to treatment assignment. Respond-
ers were offered continued treatment in a 16-week dou-
ble-blind maintenance phase. The primary objective was
to establish the efficacy of WS® 5570 600 mg/day (in one
dose) and 1200 mg/day (in two doses) during the 6 weeks
of acute treatment. Secondary objectives were to assess the
safety and tolerability of the treatments investigated. The
primary outcome measure was the intra-individual
change in the total score of the Hamilton Rating Scale for
Depression (HAM-D, 17-item version) between baseline
and the end of the 6-week acute phase. Visits took place atBMC Medicine 2006, 4:14 http://www.biomedcentral.com/1741-7015/4/14
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baseline and on days 14 and 42. The study employed an
adaptive interim analysis to enable early termination if
the presence or absence of treatment differences were
clear, or continuation of the study to a second stage with
a revised sample size.
Participants
General practitioners and psychiatrists conducted the
study. The episode was required to be of at least two
weeks' but not more than one year's duration. We
recruited male and female patients, 18 to 65 years of age,
with a diagnosis of a mild or moderate, single or recur-
rent, major depressive episode as defined by the DSM-IV
[22] (diagnostic codes for general practitioners: single epi-
sode 296.21, recurrent episode 296.31; for psychiatrists:
single episode 296.21 or 296.22, recurrent episode 296.31
and 296.32). Participants were required to have HAM-D
total score ≥18 and HAM-D item "depressive mood" ≥2 at
baseline.
Investigational treatments
Film-coated tablets of WS® 5570 containing 600 mg of dry
extract from Hypericum perforatum (drug-to-extract ratio 3–
7:1, extraction solvent methanol 80% v/v) were manufac-
tured by Dr. Willmar Schwabe Pharmaceuticals, Karl-
sruhe, Germany. Tablets containing placebo were
indistinguishable from those containing WS® 5570 in all
aspects of their appearance. During the 6 weeks of rand-
omized treatment, all patients took two film-coated tab-
lets per day, one in the morning and one in the evening.
Patients randomized to 600 mg St. John's wort extract
took one WS® 5570 tablet in the morning and one placebo
tablet in the evening. Doses were administered with liq-
uid, shortly before meals. The randomization ratio was
3:3:2 for WS® 5570 600 mg/day, WS® 5570 1200 mg/day
and placebo, respectively. This allocation ratio was chosen
to avoid unnecessary exposure of depressed patients to
placebo, to obtain more information on the active treat-
ment group, and simultaneously to minimize the power
reduction caused by unequal allocation. The Biometry
Department at Dr. Willmar Schwabe Pharmaceuticals
generated the randomization sequence in balanced
groups of eight patients using a validated random number
generator. Dr. Willmar Schwabe Pharmaceuticals pack-
aged the test drug in numbered containers according to
the randomization list and shipped them to the centers in
balanced blocks of consecutive drug numbers. Upon
enrollment, participants received a patient number;
patients who were randomized received a drug number,
sequentially allocated in the order of inclusion in the ran-
domized treatment period within the trial centers. Each
patient received only the test drug labeled with the
assigned drug number. The randomization list was kept
sealed in a secure location at Dr. Willmar Schwabe Phar-
maceuticals until all data had been entered completely
into the database, the data base had been locked, all
patients had been allocated to the analysis sets, and the
statistical analysis plan had been finalized and signed.
Measures of efficacy and safety
The primary outcome measure was the change in the total
score on the HAM-D 17-item version between day 0 and
endpoint. The secondary analysis of the HAM-D scale
included an assessment of responder and remission rates.
A responder was defined by an HAM-D total score
decrease of ≥50% between day 0 and day 42. Remission
was defined as an HAM-D total score of ≤7 points at day
42. Other secondary measures of efficacy were the total
scores (investigator ratings) on the Clinical Global
Impressions Scale (CGI), the Montgomery-Åsberg Depres-
sion Rating Scale (MADRS), and the self rating scores on
the Beck Depression Inventory (BDI), the 36-item short
form health survey (SF-36), and the patients' global self-
rating of efficacy.
Safety measures comprised physical examinations, elec-
trocardiograms and laboratory tests before and after the
double-blind treatment (blood: erythrocytes, platelets,
hemoglobin, hematocrit, leukocytes, neutrophils, eosi-
nophils, basophils, lymphocytes, monocytes, creatinine,
glucose, triglycerides, total bilirubin, cholesterol, aspar-
tate transaminase, alanine transaminase, γ-glutamyltrans-
ferase, sodium, potassium, calcium, prothrombin time,
thromboplastin time and fibrinogen; urinalysis: protein,
glucose and blood). Vital signs were tested at each of the
three visits. In addition, the patients were thoroughly
questioned about adverse events in a general inquiry dur-
ing each visit. Adverse events were coded using the Medi-
cal Dictionary for Regulatory Activities (MedDRA)
Version 5.1.
Statistical analysis
The extent of response to placebo in depression trials
tends to be variable and unpredictable [23], and striking
differences can arise in the within-group variability of
response to treatment. To avoid exposing depressed
patients to placebo unnecessarily and to minimize the risk
of insufficient statistical power, the study was planned
and conducted with an adaptive interim analysis designed
to determine whether there was sufficiently convincing
evidence, or lack of evidence, of treatment differences to
enable early termination or continuation to a second stage
with a revised sample size [24]. The interim analysis was
performed by a statistican and a programmer who were
otherwise not involved in the study.
The primary outcome measure for confirmatory treatment
group comparisons of efficacy was the absolute change in
HAM-D total score between day 0 and endpoint. The glo-
bal significance level was α = 0.05 (two-sided). For theBMC Medicine 2006, 4:14 http://www.biomedcentral.com/1741-7015/4/14
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interim analysis, the boundaries α1 = 0.0299 for rejecting
a null hypothesis and α0 = 0.30 for termination owing to
futility were applied. The global null hypothesis, predict-
ing no difference between any of the treatment group
means for the primary outcome measure, was examined
first using Bartholomew's test [25,26]. This test is espe-
cially suited to the natural ordering of dose groups and is
powerful against a variety of outcome patterns [27]. In the
event that the global null hypothesis could be rejected,
pairwise comparisons between the active treatment
groups and placebo were performed using two-sample t-
tests. Owing to the unequal sample sizes in the active
groups and the placebo group, the Welch-Satterthwaite
version of the t-test was used [28]. Application of this test-
ing strategy with local type I error rate α1 = 0.0299 in the
interim analysis guarantees control of the multiple type I
error rate α = 0.05 for the confirmatory test problem for
the primary variable [29]. Analysis of the secondary varia-
bles was descriptive and hence no adjustments were made
for the total number of comparisons. Two-sided p-values
are reported throughout.
The relationship between treatment efficacy and the sever-
ity of depression before the start of treatment was investi-
gated by explorative subgroup analyses conducted on data
from subgroups of patients with initial HAM-D total
scores split at the 25th  percentile (<20 and ≥20), the
median (<23 and ≥23) and the 75th percentile (<25 and
≥25); and on CGI item 1 severity of illness "moderately ill
or less severe" and "markedly ill or more severe".
The primary analysis of efficacy was performed on the full
analysis set (FAS) of all randomized patients for whom
some post-baseline efficacy data was available. For these
efficacy analyses, the last observation was carried forward
for patients who terminated the trial prematurely. Hence,
the reported evaluations and results correspond to base-
line-to-endpoint analyses. An additional analysis of the
primary outcome measure was performed on the per pro-
tocol analysis set (PP), which included all randomized
patients with no major protocol deviations. Safety analy-
ses were based on the safety analysis set (SAS), which
included all patients who took at least one dose of the
study medication after random assignment.
The power was estimated using Monte Carlo simulations
(10,000 replications), suited to evaluating the global null
hypothesis by Bartholomew's test followed by pairwise t-
tests based on a closed test procedure. The standard error
for the estimated power was thus approximately 0.3% for
a power of 90%. The calculations were based on the
assumption of a common standard deviation of 6 points
in the HAM-D score, estimated from previous depression
studies [2-4].
For sample sizes per group of 120 (WS® 5570 600 mg/
day), 120 (WS® 5570 1200 mg/day) and 80 (placebo),
assuming a profile of the difference in expected values
from the placebo group of 3, 3 and 0 for WS® 5570 600
mg/day, and WS® 5570 1200 mg/day and placebo, respec-
tively, and using Bartholomew's test, the power to reject
the global null hypothesis was 92.6% and the power for
additional rejection of a null hypothesis referring to the
comparison between placebo and an active treatment
group was 88.5%. Further simulations over a range of
assumed dose-response shapes for the primary outcome
variable led to similar conclusions.
Results
Patient accountability
An overview of the disposition of patients is shown in Fig-
ure 1. After giving written informed consent, 357 patients
underwent a screening examination to determine their eli-
gibility for the trial, and 332 patients were randomized
and treated: 123, 127, and 82 patients received at least one
dose of WS® 5570 600 mg/day, WS® 5570 1200 mg/day or
placebo, respectively. These 332 patients constituted the
SAS and were analyzed for safety.
Of the 332 patients randomized, 293 completed the 6-
week acute treatment: 111 (90.2%) in the WS® 5570 600
mg/day group, 108 (85.0%) in the WS® 5570 1200 mg/
day group and 74 (90.2%) in the placebo group. In total,
12 (9.8%), 19 (15.0%) and 8 (9.8%) patients discontin-
ued prematurely in the WS® 5570 600 mg/day, WS® 5570
1200 mg/day and placebo treatment groups, respectively.
The mean/median times to drop-out for these patients
were 24.9 days/25 days, 23.5 days/26 days and 30.8 days/
27 days, respectively. The primary reason for early with-
drawal was "lost to follow-up" (4.1% for WS® 5570 600
mg/day, 6.3% for WS® 5570 1200 mg/day and 6.1% for
placebo).
Eight patients had no post-baseline efficacy data and were
thus excluded from the efficacy analyses: 4 in the WS®
5570 600 mg/day group, 3 in the WS® 5570 1200 mg/day
group and 1 in the placebo group. The remaining 324
patients constituted the FAS and were analyzed for effi-
cacy.
In addition to the 8 patients with no post-baseline efficacy
data, there were 15, 20 and 12 patients with relevant pro-
tocol violations in the WS® 5570 600 mg/day, WS® 5570
1200 mg/day and placebo treatment groups, respectively.
Decisions as to the relevance of the protocol deviations
were made before the code was broken. Premature with-
drawal was the most frequent relevant protocol violation
in all treatment groups, followed by insufficient treatment
compliance. The percentage of non-compliant patients
was slightly higher in the WS® 5570 1200 mg/day groupBMC Medicine 2006, 4:14 http://www.biomedcentral.com/1741-7015/4/14
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Patient accounting and datasets for analysis Figure 1
Patient accounting and datasets for analysis.
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(18.9%) than in the WS® 5570 600 mg/day (15.4%) and
the placebo groups (15.9%). The PP analysis set com-
prised the 277 patients without relevant protocol viola-
tions: 104 each in the WS® 5570 groups and 69 in the
placebo group.
Baseline characteristics
Demographic and clinical measures at baseline are shown
in Table 1. There were no significant differences in demo-
graphic characteristics among the three treatment groups.
For the HAM-D, MADRS and BDI, a higher value indicates
more severe impairment, whereas for the SF-36 a lower
score indicates more severe impairment. The HAM-D total
scores (primary outcome measure) were comparable
among all three groups at baseline. The CGI assessment at
baseline did not indicate a higher degree of pathology in
the placebo group than in the two WS® 5570 groups,
whereas for the MADRS and SF-36 the patients in the pla-
cebo group exhibited slightly more severe baseline
impairment than those in the two WS® 5570 groups,
though these differences were not significant. For the BDI,
the slightly more severe baseline impairment exhibited for
the placebo group compared to the two WS® 5570 groups
was statistically significant.
Efficacy
Bartholomew's test yielded a p-value of p < 0.001<α1 =
0.0299, enabling rejection of the global null hypothesis
predicting no difference in mean values between the treat-
ment groups. Thus, the primary objectives of the trial were
fulfilled, rendering it unnecessary to perform a second
stage.
WS® 5570 600 mg/day and WS® 5570 1200 mg/day were
demonstrated to be significantly superior to placebo in
reducing the HAM-D total score after 42 days of acute
treatment (FAS: test statistic = 0.09, p < 0.001; PPS: test
statistic = 0.08, p < 0.001). Average total HAM-D scores
decreased monotonically in all three groups between the
start of randomized treatment and day 42 (Figure 2).
Table 2 compares the mean HAM-D scores at baseline and
after 14 and 42 days of treatment. The mean HAM-D total
score was reduced approximately twice as much for the
600 mg/day and 1200 mg/day WS® 5570 groups as for the
placebo group. In all three groups, median HAM-D scores
decreased by 4 points over the first two weeks. However,
patients randomized to either dose of WS® 5570 contin-
ued to improve between day 14 and day 42 at a rate com-
parable to that of the initial two weeks, whereas the study
participants in the placebo group showed only a small
additional average improvement beyond day 14. No sig-
nificant difference was observed between the WS® 5570
600 mg/day and WS®  5570 1200 mg/day treatment
groups. The median decrease in HAM-D scores between
day 42 and day 0 was 13 points for both WS® 5570 groups
and 3 points for the placebo group. The results obtained
from the PP analysis were consistent with those of the FAS
analysis.
Subgroup analyses were performed to assess the influence
of the pre-treatment severity of depression on the change
Table 1: Demographic and clinical characteristics at baseline for patients with a major depressive episode (full analysis set)
Characteristic WS® 5570 600 mg/day 
N = 119
WS® 5570 1200 mg/day 
N = 124
Placebo 
N = 81
p-value
Sex: 0.13*
Female n (%) 67 (56.3) 82 (66.1) 56 (69.1)
Male n (%) 52 (43.7) 42 (33.9) 25 (30.9)
Age (years) Mean ± SD 46.3 ± 11.5 46.1 ± 10.7 46.9 ± 11.8 0.69§
HAM-D total score Mean ± SD 22.8 ± 3.3 22.6 ± 3.8 23.6 ± 4.2 0.31
CGI severity of illness: 0.20*
Mildly or moderately ill n (%) 67 (56.3) 62 (50.0) 46 (56.8)
Markedly or severely ill n (%) 52 (43.7) 62 (50.0) 35 (43.2)
MADRS Mean ± SD 27.2 ± 5.5 26.3 ± 6.0 28.0 ± 6.2 0.09§
BDI Mean ± SD 23.2 ± 7.9 23.3 ± 8.0 25.7 ± 8.9 0.05§
SF-36 summary measure mental health Mean ± SD 25.1 ± 11.7 27.7 ± 13.3 23.7 ± 11.1 0.16§
For the HAM-D, MADRS and BDI, a higher value indicates more severe impairment whereas for the SF-36, a lower score indicates more severe 
impairment.
*Two-sided chi-square test
§Two-sided Kruskal-Wallis testBMC Medicine 2006, 4:14 http://www.biomedcentral.com/1741-7015/4/14
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in HAM-D total score under treatment with WS® 5570 or
placebo. The subgroups were based on initial HAM-D
total scores split at the 25th percentile (<20 and ≥ 20), the
median (<23 and ≥ 23) and the 75th percentile (<25 and ≥
25); and on CGI item 1 severity of illness "moderately ill
or less severe" and "markedly ill or more severe". The
results are shown in Table 3. Owing to the different and in
some cases small sample sizes of the subgroups, the p-val-
ues for these analyses are to be interpreted with caution.
WS® 5570 was consistently more effective than placebo in
patients with both less severe and more severe baseline
impairment. This applied to all the cutoffs between
"lower" and "higher" baseline severity we investigated.
The relationship between baseline demographic factors
and recurrence of depression on improvement in HAM-D
total score between baseline and the end of randomized
acute treatment was also investigated. WS® 5570 was con-
sistently more effective than placebo in all subgroups
investigated; no systematic relationship between treat-
ment efficacy and age, sex, or recurrence of depression was
observed.
Secondary efficacy outcome measures are shown in Table
4. Responders were defined as patients with ≥50%
decrease in HAM-D total score between day 0 and day 42.
The responder rates were approximately 70% and 61% in
the WS® 5570 600 mg/day and WS® 5570 1200 mg/day
groups, respectively, whereas the responder rate in the pla-
cebo group was approximately 32% (FAS: χ2 = 27.55, df =
1; p < 0.001 for WS® 5570 600 mg/day vs placebo; χ2 =
16.70, df = 1; p < 0.001 for WS® 5570 1200 mg/day vs pla-
cebo). The clinically important criterion of remission was
defined as a HAM-D total score ≤7 points at end of treat-
ment. The number of patients who met this criterion was
about 33% in the WS® 5570 600 mg/day group, about
40% in the WS® 5570 1200 mg/day group and about 15%
in the placebo group (FAS, χ2 = 8.16, df = 1; p = 0.004 for
WS® 5570 600 mg/day versus placebo; χ2 = 15.11, df = 1;
p < 0.001 for the comparison of WS® 5570 1200 mg/day
versus placebo; χ2 = 1.49, df = 1; p = 0.22 for the compar-
ison of WS® 5570 600 mg/day and WS® 5570 1200 mg/
day). Results obtained for the PP analysis were analogous.
Table 2: Comparison of HAM-D scores for patients with a major depressive episode over 6-week treatment with WS® 5570 or placebo 
(full analysis set; last observation carried forward)
HAM-D measure WS® 5570 600 
mg/day N = 119
WS® 5570 1200 
mg/day N = 124
Placebo N = 81 p-value
WS® 5570 600 mg/
day vs placebo
WS® 5570 1200 
mg/day vs placebo
Total score (mean ± SD) Day 0 22.8 ± 3.3 22.6 ± 3.8 23.6 ± 4.2 0.14 0.09
Day 14 17.9 ± 6.3 18.2 ± 6.6 19.1 ± 20 0.23 0.34
Day 42 11.2 ± 7.0 11.8 ± 8.3 17.6 ± 8.8 <0.001 <0.001
Difference vs day 0 (mean ± SD) Day 14 -4.9 ± 5.1 -4.5 ± 4.7 -4.5 ± 5.4 0.65 0.95
Day 42 -11.6 ± 6.4 -10.8 ± 7.3 -6.0 ± 8.1 <0.001 <0.001
Mean reduction vs day 0 (%) Day 14 22.0% 20.9% 16.7% 0.54 0.77
Day 42 57.9% 57.1% 16.7% <0.001 <0.001
Comparison vs placebo for 
difference day 42 vs day 0
WS® 5570 600 mg/day vs placebo WS® 5570 1200 
mg/day vs placebo
Differences in means* -5.6 -4.8
95% confidence interval [-7.7, -3.6] [-6.9, -2.6]
p-value <0.001 <0.001
*A negative difference denotes a more favorable outcome in the treatment group named first.
Change in mean total HAM-D score in patients suffering a  major depressive episode over the 6-week treatment with  WS® 5570 or placebo (full analysis set, means and 95% confi- dence intervals) Figure 2
Change in mean total HAM-D score in patients suffering a 
major depressive episode over the 6-week treatment with 
WS® 5570 or placebo (full analysis set, means and 95% confi-
dence intervals).
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All items of the CGI showed substantially greater
improvements in the two WS® 5570 groups than in pla-
cebo (Table 4). In about 40% of the patients treated with
the herbal extract and 17% of those randomized to pla-
cebo, the severity of depression was rated as having been
alleviated by at least two categories (e.g. from "markedly
ill" to "mildly ill", or from "moderately ill" to "borderline
mentally ill"; FAS). More than 60% of patients in both
WS® 5570 groups and about 31% in the placebo group
were much or very much improved. In approximately
35% of the patients treated with WS® 5570 and 16% of the
placebo group, the investigator observed a "marked ther-
apeutic effect" of the study drug. All pairwise comparisons
between WS® 5570 600 mg/day or WS® 5570 1200 mg/day
and placebo showed two-sided p-values of p < 0.01; χ2 =
7.63, df = 1. The differences between the CGI results in the
two WS® 5570 groups were marginal.
All three treatment groups showed comparable decreases
in MADRS mean total score of about 5 points between day
0 and day 14 (Table 4). While the MADRS total scores
continued to decrease in the WS® 5570 groups between
days 14 and 42, patients randomized to placebo showed
only marginal changes between the visits at day 14 and
day 42. The score reductions were approximately twice as
great in the two WS® 5570 groups as in the placebo group
at treatment end (t = 4.75, df = 159; p < 0.001 for pairwise
comparisons of WS® 5570 600 mg/day vs placebo and t =
3.69, df = 158; p < 0.001 for WS® 5570 1200 mg/day vs
placebo). At day 14 as well as at day 42, there were negli-
gible differences between WS® 5570 600 mg/day and WS®
5570 1200 mg/day in the change of MADRS total score
against baseline.
To supplement the observer ratings of severity of depres-
sion obtained with the HAM-D and the MADRS, the BDI
self-rating scale was administered at baseline and at end of
treatment. With average score decreases around 8 points
in the two WS® 5570 groups versus 3.7 points in the pla-
cebo group, patients randomized to WS® 5570 subjec-
tively reported substantially greater symptom alleviation
than those who received placebo during the double-blind
acute treatment. This corresponded to average score
decreases of approximately 35% for both WS®  5570
groups and 14.2% for placebo. The pairwise comparisons
between WS® 5570 600 mg/day and placebo or WS® 5570
1200 mg/day and placebo showed p-values of p < 0.001
with t = 3.90, df = 179 and t = 3.62, df = 185. There were
no significant differences between the average BDI self-
ratings of the two WS® 5570 groups.
The 36 items of the SF-36 can be divided into the two
summary measures physical health and mental health.
Following comparable baseline values for the mental
health summary measure among the three treatment
groups (Table 1), the patients randomized to WS® 5570
showed average improvements over baseline for the men-
tal health summary measure about twice as great as those
in the placebo group (t = 4.74, df = 190; p < 0.001 for WS®
5570 600 mg/day vs placebo; t = 3.77, df = 201; p < 0.001
for WS® 5570 1200 mg/day vs placebo).
At the end of the 6-week treatment, a global self-rating of
efficacy was obtained from 107 patients in the WS® 5570
600 mg/day group, 105 patients in the WS® 5570 1200
mg/day group and 69 patients in the placebo group. The
efficacy of the investigational treatment was rated "good"
Table 3: Relative decreases in HAM-D scores for subgroups of patients with a major depressive episode after 6 weeks of treatment 
with WS® 5570 or placebo (full analysis set, last observation carried forward)
Subgroup based on baseline score Mean % decrease ± SD, number of patients p-value
WS® 5570 600 
mg/day N = 119
WS® 5570 1200 
mg/day N = 124
Placebo N = 81 WS® 5570 600 mg/
day vs placebo
WS® 5570 1200 
mg/day vs placebo
Baseline HAM-D total score cutoff 
20 (split at 25th percentile)
<20 54.2 ± 26.3, 25 56.0 ± 29.9, 31 32.7 ± 40.5, 14 0.09 0.07
≥ 20 51.1 ± 28.3, 94 46.4 ± 32.5, 93 24.4 ± 33.6, 67 <0.001 <0.001
Baseline HAM-D total score cutoff 
23 (split at median)
<23 55.5 ± 28.1, 56 53.1 ± 29.7, 64 26.8 ± 38.8, 37 <0.001 <0.001
≥ 23 48.4 ± 27.4, 63 44.2 ± 33.9, 60 25.1 ± 31.4, 44 <0.001 <0.01
Baseline HAM-D total score cutoff 
25 (split at 75th percentile)
<25 53.6 ± 27.3, 83 52.8 ± 30.2, 85 28.6 ± 37.7, 49 <0.001 <0.001
≥ 25 47.4 ± 28.9, 36 40.2 ± 34.5, 39 21.7 ± 29.8, 32 <0.001 0.02
Baseline CGI item 1, severity of 
illness
<5* 51.2 ± 28.7, 67 49.9 ± 31.5, 62 28.0 ± 36.1, 46 <0.001 <0.01
≥ 5§ 52.4 ± 26.9, 52 47.7 ± 32.7, 62 23.1 ± 33.3, 35 <0.001 <0.001
* "Moderately ill or less severe"
§ "Markedly ill or more severe"BMC Medicine 2006, 4:14 http://www.biomedcentral.com/1741-7015/4/14
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or "very good" for 76 (71.0%) randomized to WS® 5570
600 mg/day, 67 (63.8%) treated with WS® 5570 1200 mg/
day and 23 (33.3%) in the placebo group (chi-square test:
WS® 5570 600 mg/day vs placebo p < 0.001; WS® 5570
1200 mg/day vs placebo p < 0.001). Treatment efficacy
was rated "bad" or "very bad" by 18 (16.8%) patients in
the WS® 5570 600 mg/day group, 25 (23.8%) in the WS®
5570 1200 mg/day group, and 36 (52.2%) randomized to
placebo.
Safety and tolerability
The adverse events that occurred during the treatment
phase are shown in Table 5. The reported p-values were
calculated using Fisher's exact test. The most frequently
reported adverse events were related to gastrointestinal
disorders, affecting 19.5% (24 of 123) of the patients in
the WS® 5570 600 mg/day group, 23.6% (30 of 127) of
those in the WS® 5570 1200 mg/day group and 15.9% (13
of 82) of those in the placebo group. None of the frequen-
cies showed any dose-related relationship. Serious adverse
events were reported in 3 patients after randomization: 1
patient in the WS® 5570 600 mg/day group (with an event
of tendon rupture attributable to accidental injury) and 2
in the WS® 5570 1200 mg/day group (with events of
depression aggravation and acute stress disorder, attribut-
able to the underlying disease and not tolerability issues).
One serious adverse event (suicide attempt) occurred after
screening but before randomization. All serious adverse
events were classified as serious owing to hospitalization.
There were few premature withdrawals due to adverse
events: 2 (1.6%) patients in the WS® 5570 600 mg/day
group (with events of erythema and herpetic stomatitis)
and 4 (3.2%) in the WS® 5570 1200 mg/day group (with
events of upper abdominal pain, stomatitis, acute stress
disorder and metorrhagia).
Adverse events were assessed for causal relationship to the
treatment under investigation before unblinding. Such
Table 4: Secondary efficacy measures for patients with a major depressive episode treated over 6-weeks with WS® 5570 or placebo 
(full analysis set, last observation carried forward)
p-value
Secondary efficacy measure* WS® 5570 600 
mg/day N = 119
WS® 5570 1200 
mg/day N = 124
Placebo N = 81 WS® 5570 600 
mg/day vs placebo
WS® 5570 1200 
mg/day vs placebo
n (%)
Responder rate (decrease ≥ 50% in total 
HAM-D score between day 0 and day 42)
83 (69.8) 76 (61.3) 26 (31.1) <0.001 <0.001
Remission rate (≤ 7 points in total HAM-D 
score at day 42)
39 (32.8) 50 (40.3) 12 (14.8) <0.01 <0.001
CGI, item 1:
improved by ≥ 2 categories 46 (38.7) 54 (43.6) 14 (17.3) 0.001 <0.001
CGI, item 2:
much or very much improved 76 (63.9) 77 (62.1) 25 (30.9) <0.001 <0.001
CGI, item 3:
marked therapeutic effect 40 (33.6) 47 (37.9) 13 (16.1) 0.006 <0.001
Mean ± SD
MADRS absolute change
day 14 – day 0 -5.3 ± 7.7 -4.4 ± 5.5 -5.0 ± 6.6 0.80 0.46
day 42 – day 0 -13.3 ± 9.3 -11.8 ± 9.3 -6.5 ± 10.4 <0.001 <0.001
MADRS relative decrease (%)
day 14 – day 0 19.5 ± 26.7 17.5 ± 22.8 18.1 ± 25.1 0.72 0.85
day 42 – day 0 48.9 ± 31.6 45.6 ± 34.2 22.2 ± 36.6 <0.001 <0.001
BDI absolute change
(day 42 – day 0) -8.3 ± 8.5 -8.0 ± 9.1 -3.7 ± 7.9 <0.001 <0.001
BDI relative change (%)
day 42 – day 0 34.6 ± 34.0 34.1 ± 36.8 14.2 ± 36.9 <0.001 <0.001
SF-36 summary measures (day 42 – day 0)
Physical health 3.8 ± 18.3 5.8 ± 16.3 2.2 ± 13.7 0.47 0.09
Mental health 18.1 ± 18.7 16.5 ± 21.9 6.8 ± 14.6 <0.001 <0.001
*For the HAM-D, the MADRS and the BDI, higher values indicate more severe impairment whereas for the SF-36, lower values indicate more severe 
impairmentBMC Medicine 2006, 4:14 http://www.biomedcentral.com/1741-7015/4/14
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events were considered potentially related to the treat-
ment for 30 (24.4%), 31 (24.4%) and 13 (15.9%)
patients in the WS® 5570 600 mg/day, 1200 mg/day and
placebo groups, respectively. Among these potentially
attributable adverse events, the most frequent were gas-
trointestinal disorders, which were assessed as possibly
related in all three treatment-groups. No dose-related rela-
tionship was observed. All other adverse events for which
a causal relationship with the investigational treatments
could not be excluded occurred in not more than two
patients in any group. Two women treated with WS® 5570
experienced metorrhagia and one reported menorrhagia;
these adverse events have previously been associated with
the administration of Hypericum extract. Furthermore, one
case of mildly increased sensitivity to sunlight and
another case of moderate sunburn were assessed as related
to WS®  5570 treatment; photosensitivity reactions are
among the known side effects of Hypericum extract.
None of the laboratory safety parameters showed any rel-
evant changes in the mean, and incidences of clinically
relevant deviations from the reference ranges were compa-
rable between the study groups. No noteworthy changes
were observed in vital signs, physical examination or elec-
trocardiograms.
Discussion
Efficacy
The results of this study demonstrate the superior antide-
pressant efficacy of WS® 5570 600 mg/day (in one dose)
and of WS® 5570 1200 mg/day (in two daily doses) com-
pared to placebo in the treatment of patients with a mild
or moderate major depressive episode after 6 weeks of
treatment. Over the first two weeks, the mean decreases in
HAM-D scores were nearly the same, about 4 points in all
three groups. Over the full 6 weeks, mean decreases in
HAM-D scores were approximately 11 points for both WS®
5570 groups and 6 points for the placebo group; the dif-
ference of 5 points was significant (FAS: t = 5.26, df = 145;
p < 0.001 for WS® 5570 600 mg/day vs placebo; t = 4.32,
df = 159; p < 0.001 for WS® 5570 1200 mg/day vs pla-
cebo). The findings of the analyses with the FAS were fully
supported by the PP analyses.
On a descriptive level, the antidepressant effects of WS®
5570 and placebo were comparable during the first two
weeks of treatment, indicating that without a placebo run-
in phase, factors other than the pharmacological action of
Hypericum extract may have initially contributed to the
observed relief of depressive symptoms. However, the
majority of patients randomized to placebo showed only
limited or no improvement between day 14 and day 42,
Table 5: Adverse events reported during the 6-week treatment with WS® 5570 or placebo (safety analysis set)
Type of adverse event (MedDRA 
System Organ Class)
Number (%) of patients with adverse events* p-value
WS® 5570 600 
mg/day N = 123
WS® 5570 1200 
mg/day N = 127
Placebo N = 82 WS® 5570 600 
mg/day vs placebo
WS® 5570 1200 
mg/day vs placebo
All adverse events 49 (39.8) 50 (39.4) 22 (26.8) 0.07 0.07
Ear and labyrinth disorders 3 (2.4) 2 (1.6) 1 (1.2) 0.65 1.00
Eye disorders 0 (0.0) 1 (0.8) 0 (0.0) 1.00 1.00
Gastrointestinal disorders 24 (19.5) 30 (23.6) 13 (15.9) 0.58 0.22
General disorders and administration site 
conditions
2 (1.6) 2 (1.6) 0 (0.0) 0.52 0.52
Infections and infestations 7 (5.7) 4 (3.2) 2 (2.4) 0.32 1.00
Injury, poisoning and procedural 
complications
1 (0.8) 1 (0.8) 1 (1.2) 1.00 1.00
Investigations 1 (0.8) 0 (0.0) 0 (0.0) 1.00 1.00
Metabolism and nutrition disorders 1 (0.8) 1 (0.8) 1 (1.2) 1.00 1.00
Musculosceletal and connective tissue 
disorder
1 (0.8) 2 (1.6) 1 (1.2) 1.00 1.00
Nervous system disorder 6 (4.9) 6 (4.7) 2 (2.4) 0.48 0.49
Psychiatric disorders 2 (1.6) 2 (1.6) 0 (0.0) 0.52 0.52
Renal and unrinary disorders 1 (0.8) 0 (0.0) 0 (0.0) 1.00 1.00
Reproductive system and breast disorders 1 (0.8) 2 (1.6) 0 (0.0) 1.00 0.52
Respiratory, thoracic and mediastinal 
disorders
4 (3.3) 5 (3.9) 2 (2.4) 1.00 0.71
Skin and subcutaneous disorders 4 (3.3) 2 (1.6) 4 (4.9) 0.72 0.21
Vascular disorders 1 (0.8) 1 (0.8) 0 (0.0) 1.00 1.00
Adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) Version 5.1.
*Patients may have experienced more than one adverse event.BMC Medicine 2006, 4:14 http://www.biomedcentral.com/1741-7015/4/14
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whereas patients treated with WS® 5570 600 mg/day and
WS®  5570 1200 mg/day continued to improve at an
almost constant rate until the end of this study period, so
the treatment group differences observed at the end of the
6-week acute phase can be attributed to the pharmacolog-
ical effect of the herbal extract.
The effect size observed in this study was greater than that
observed in a study with 300 mg WS® 5570 three times
daily (i.e. WS®  5570 900 mg/day) and placebo [4].
Although the mean HAM-D scores at day 42 for the WS®
5570 900 mg/day group in that study were similar to the
scores observed for WS® 5570 600 mg/day and WS® 5570
1200 mg/day in the present study, the mean scores for
patients randomized to placebo were lower than those of
the placebo patients observed in the present study.
The difference of about 30% in responder rates (69.8% in
the WS® 5570 600 mg/day group, 61.3% in the WS® 5570
1200 mg/day group and 31.1% in the placebo group) was
significant (FAS: χ2 = 27.55, df = 1; p < 0.001 for WS® 5570
600 mg/day vs placebo; χ2 = 16.70, df = 1; p < 0.001 for
WS® 5570 1200 mg/day vs placebo). The differences in
remission rates (32.8% in the WS® 5570 600 mg/day
group, 40.3% in the WS® 5570 1200 mg/day group and
14.8% in the placebo group) were also significant (FAS, χ2
= 8.16, df = 1; p < 0.01 for the comparison of the WS® 5570
600 mg/day group versus placebo and χ2 = 15.11, df = 1;
p < 0.001 for the comparison of the WS® 5570 1200 mg/
day group versus placebo). These effects were also greater
than those observed between 300 mg WS® 5570 three
times daily and placebo [4].
Other secondary measures of treatment efficacy, i.e. the
CGI and MADRS observer rating scales, the BDI self-rating
scale, the SF-36 and the patient global self-rating, showed
results consistent with those obtained for the primary out-
come measure: statistically significant changes between
baseline and day 42 for WS® 5570 600 mg/day and 1200
mg/day compared to placebo.
Descriptively, the remission rates were about 8% greater
for the WS® 5570 1200 mg/day group than for the WS®
5570 600 mg/day group, i.e. there is a possible dose-
dependency. For most of the outcome measures assessed,
only minor differences in efficacy were observed between
WS® 5570 600 mg/day and 1200 mg/day. This applied to
the analysis data sets as a whole as well as to subgroups
defined by baseline severity of depression. Thus, the dose
of WS®5570 600 mg/day can be considered sufficiently
efficacious; doubling the dosage increases the chances of
therapeutic success only slightly.
Safety and tolerability
For all three treatment-groups, the highest frequencies of
adverse events were observed during the first two weeks of
acute treatment. Because this effect was observed in all
three treatment groups and in the absence of a placebo
run-in phase, it is likely to have been related to a nonspe-
cific, non-drug-related effect based on the patients' and
investigators' expectations or to the patients' initial sever-
ity of depression (known to increase vulnerability to vari-
ous kinds of adverse experiences).
During the 6-week acute treatment, the WS® 5570 600 mg/
day and 1200 mg/day groups showed a slightly higher fre-
quency of adverse events than the placebo group (0.012
and 0.013 versus 0.008 events per day of exposure, respec-
tively). However, there were no meaningful differences in
incidence rates in any of the System Organ Classes of the
MedDRA system. Furthermore, when only potentially
attributable events were considered, marginal treatment
group differences in adverse event incidence were
observed: 0.007, 0.007 and 0.005 events per day of expo-
sure during acute treatment for WS® 5570 600 mg/day,
1200 mg/day and placebo groups, respectively. The
WS®5570 1200 mg/day dose was as well tolerated as the
600 mg/day dose.
Potentially attributable adverse events included gastroin-
testinal disorders, menstrual complications and photo-
sensitivity reactions. The events occurred with low
frequencies, and all three types of events have been asso-
ciated with Hypericum  extract as rare, transient adverse
reactions. Aside from these three types, the results of this
study do not point to any drug-specific adverse events. A
systematic literature review of the adverse effects of St.
John's wort is given by Hammerness et al. [30].
WS® 5570 had no meaningful influence on laboratory
measures, physical findings, vital signs or ECG parame-
ters.
Conclusion
This trial demonstrates that Hypericum extract WS® 5570
600 mg/day (given once daily) and WS® 5570 1200 mg/
day (divided into two daily doses) are both efficacious in
the treatment of mild or moderate unipolar major depres-
sion. This principal finding was consistent across several
validated investigator- and self-rating scales, across the
participating centers, and for different analysis data sets
(including or excluding patients with major protocol vio-
lations). Decreases in average HAM-D total score versus
baseline were approximately 6 and 5 points greater after
the 6-week treatment for WS® 5570 600 mg/day and WS®
5570 1200 mg/day, respectively, than for placebo. The
responder rates of 70% and 61% versus 32% and the
remission rates of 33% and 40% versus 15% for WS® 5570BMC Medicine 2006, 4:14 http://www.biomedcentral.com/1741-7015/4/14
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600 mg/day, WS® 5570 1200 mg/day and placebo, respec-
tively, also underscore the clinical relevance of the
observed effect. The interim analysis showed statistical
significance versus placebo in favor of both treatment reg-
imens of WS®5570, allowing rejection of the null hypoth-
eses in accordance with the biometrical design pre-
specified in the protocol. Hence, the study could be termi-
nated early owing to the proof of efficacy for both active
treatment groups.
The primary outcome measure, the HAM-D total score
change versus baseline after 6 weeks, and the psychiatric
scales administered as secondary efficacy measures, indi-
cate no meaningful differences in efficacy between WS®
5570 600 mg/day (in one dose) and 1200 mg/day (in two
doses). However, more patients in the 1200 mg/day dose
met the clinically important criterion of remission (HAM-
D total score ≤7 points at treatment end) in descriptive
analyses.
WS® 5570 at doses of 600 mg/day and 1200 mg/day was
well tolerated. Treatment with Hypericum extract was asso-
ciated with a slightly higher rate of adverse events than
treatment with placebo, but these differences were minor,
particularly for potentially attributable events. All poten-
tially attributable adverse events were non-serious and
transient and reflected the known profile of adverse events
for Hypericum extract. Thus, the trial did not reveal any
previously unknown risks in treatment with Hypericum
extract.
Although the WS® 5570 1200 mg/day dose did not prove
to be significantly more effective than the 600 mg/day
dose, the doubled dose was equally safe and well toler-
ated.
In conclusion, Hypericum extract WS® 5570 600 mg/day
and 1200 mg/day were shown to be safe and more effica-
cious than placebo in the 6-week treatment of patients
suffering from a mildly to moderately intense major
depressive episode.
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